Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity

Journal of Virology

Volumn 82, Issue 6, 2008, Pages 3078-3089

  Joseph, Aviva ^a   Jian, Hua Zheng ^a   Follenzi, Antonia ^a   DiLorenzo, Teresa ^a   Sango, Kaori ^a   Hyman, Jaime ^a   Chen, Ken ^a   Piechocka Trocha, Alicja ^b,c   Brander, Christian ^b,c   Hooijberg, Erik ^d   Vignali, Dario A ^e   Walker, Bruce D ^b,c   Goldstein, Harris ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; LENTIVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; LYMPHOCYTE TRANSFORMATION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC ENGINEERING; GENETIC VECTORS; HIV-1; HUMANS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 40149106131     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01812-07     Document Type: Article

References (70)

1. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93:4102-4107.
2. Appay, V., D. F. Nixon, S. M. Donahoe, G. M. Gillespie, T. Dong, A. King, G. S. Ogg, H. M. Spiegel, C. Conlon, C. A. Spina, D. V. Havlir, D. D. Richman, A. Waters, P. Easterbrook, A. J. McMichael, and S. L. Rowland-Jones. 2000. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:63-75.
3. Arnold, P. Y., A. R. Burton, and D. A. Vignali. 2004. Diabetes incidence is unaltered in glutamate decarboxylase 65-specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer. J. Immunol. 173:3103-3111.
4. Bollard, C. M., I. Kuehnle, A. Leen, C. M. Rooney, and H. E. Heslop. 2004. Adoptive immunotherapy for posttransplantation viral infections. Biol. Blood Marrow Transplant. 10:143-155.
5. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205-211.
6. Brander, C., K. E. Hartman, A. K. Trocha, N. G. Jones, R. P. Johnson, B. Korber, P. Wentworth, S. P. Buchbinder, S. Wolinsky, B. D. Walker, and S. A. Kalams. 1998. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J. Clin. Investig. 101: 2559-2566.
7. Brodie, S. J., D. A. Lewinsohn, B. K. Patterson, D. Jiyamapa, J. Krieger, L. Corey, P. D. Greenberg, and S. R. Riddell. 1999. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:34-41.
8. Brown, B. K., J. M. Darden, S. Tovanabutra, T. Oblander, J. Frost, E. Sanders-Buell, M. S. de Souza, D. L. Birx, F. E. McCutchan, and V. R. Polonis. 2005. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79:6089-6101.
9. Cannon, P. M., S. Matthews, N. Clark, E. D. Byles, O. Iourin, D. J. Hockley, S. M. Kingsman, and A. J. Kingsman. 1997. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J. Virol. 71:3474-3483.
10. Cerundolo, V., J. Alexander, K. Anderson, C. Lamb, P. Cresswell, A. McMichael, F. Gotch, and A. Townsend. 1990. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 345: 449-452.
11. Chang, H. C., Z. Bao, Y. Yao, A. G. Tse, E. C. Goyarts, M. Madsen, E. Kawasaki, P. P. Brauer, J. C. Sacchettini, S. G. Nathenson, et al. 1994. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. Proc. Natl. Acad. Sci. USA 91:11408-11412.
12. Consiglio, A., A. Gritti, D. Dolcetta, A. Follenzi, C. Bordignon, F. H. Gage, A. L. Vescovi, and L. Naldini. 2004. Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc. Natl. Acad. Sci. USA 101:14835-14840.
13. Cooper, L. J. N., M. Kalos, D. A. Lewinsohn, S. R. Riddell, and P. D. Greenberg. 2000. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74:8207-8212.
14. Dadachova, E., M. C. Patel, S. Toussi, C. Apostolidis, A. Morgenstern, M. W. Brechbiel, M. K. Gorny, S. Zolla-Pazner, A. Casadevall, and H. Goldstein. 2006. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 3:e427.
15. Dagarag, M., H. Ng, R. Lubong, R. B. Effros, and O. O. Yang. 2003. Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J. Virol. 77:3077-3083.
16. Day, C. L., A. K. Shea, M. A. Altfeld, D. P. Olson, S. P. Buchbinder, F. M. Hecht, E. S. Rosenberg, B. D. Walker, and S. A. Kalams. 2001. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J. Virol. 75:6279-6291.
17. Dela Cruz, C. S., R. Tan, S. L. Rowland-Jones, and B. H. Barber. 2000. Creating HIV-1 reverse transcriptase cytotoxic T lymphocyte target structures by HLA-A2 heavy chain modifications. Int. Immunol. 12:1293-1302.
18. De Maria, A., C. Cirillo, and L. Moretta. 1994. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J. Infect. Dis. 170:1296-1299.
19. Ferbas, J., A. H. Kaplan, M. A. Hausner, L. E. Hultin, J. L. Matud, Z. Liu, D. L. Panicali, H. Nerng-Ho, R. Detels, and J. V. Giorgi. 1995. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J. Infect. Dis. 172: 329-339.
20. Follenzi, A., L. E. Ailles, S. Bakovic, M. Geuna, and L. Naldini. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-222.
21. Follenzi, A., and L. Naldini. 2002. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346:454-465.
22. Frahm, N., P. Kiepiela, S. Adams, C. H. Linde, H. S. Hewitt, K. Sango, M. E. Feeney, M. M. Addo, M. Lichterfeld, M. P. Lahaie, E. Pae, A. G. Wurcel, T. Roach, M. A. St. John, M. Altfeld, F. M. Marincola, C. Moore, S. Mallal, M. Carrington, D. Heckerman, T. M. Allen, J. I. Mullins, B. T. Korber, P. J. Goulder, B. D. Walker, and C. Brander. 2006. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 7:173-178.
23. Gotch, F., A. Gallimore, and A. McMichael. 1996. Cytotoxic T cells - protection from disease progression - protection from infection. Immunol. Lett. 51:125-128.
24. Goulder, P. J., R. E. Phillips, R. A. Colbert, S. McAdam, G. Ogg, M. A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A. J. McMichael, and S. Rowland-Jones. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
25. Goulder, P. J., A. K. Sewell, D. G. Lalloo, D. A. Price, J. A. Whelan, J. Evans, G. P. Taylor, G. Luzzi, P. Giangrande, R. E. Phillips, and A. J. McMichael. 1997. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J. Exp. Med. 185:1423-1433.
26. Harrer, T., E. Harrer, S. A. Kalams, P. Barbosa, A. Trocha, R. P. Johnson, T. Elbeik, M. B. Feinberg, S. P. Buchbinder, and B. D. Walker. 1996. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J. Immunol. 156:2616-2623.
27. Heemskerk, M. H., R. S. Hagedoorn, M. A. van der Hoorn, L. T. van der Veken, M. Hoogeboom, M. G. Kester, R. Willemze, and J. H. Falkenburg. 2007. Efficiency of T-cell receptor expression in dual-specific T celts is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109:235-243.
28. Herr, W., J. Schneider, A. W. Lohse, K. H. Meyer zum Buschenfelde, and T. Wolfel. 1996. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods 191: 131-142.
29. Holmberg, K., S. Mariathasan, T. Ohteki, P. S. Ohashi, and N. R. Gascoigne. 2003. TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J. Immunol. 171:2427-2434.
30. Holst, J., K. M. Vignali, A. R. Burton, and D. A. Vignali. 2006. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat. Methods 3:191-197.
31. Hughes, M. S., Y. Y. Yu, M. E. Dudley, Z. Zheng, P. F. Robbins, Y. Li, J. Wunderlich, R. G. Hawley, M. Moayeri, S. A. Rosenberg, and R. A. Morgan. 2005. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16:457-472.
32. Huynen, M. A., and A. U. Neumann. 1996. Rate of killing of HIV-infected T cells and disease progression. Science 272:1962.
33. Jassoy, C., and B. D. Walker. 1997. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Semin. Immunopathol. 18: 341-354.
34. Johnson, L. A., B. Heemskerk, D. J. Powell, Jr., C. J. Cohen, R. A. Morgan, M. E. Dudley, P. F. Robbins, and S. A. Rosenberg. 2006. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177:6548-6559.
35. Joseph, A., I. Louria-Hayon, A. Plis-Finarov, E. Zeira, Z. Zakay-Rones, E. Raz, T. Hayashi, K. Takabayashi, Y. Barenholz, and E. Kedar. 2002. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20:3342-3354.
36. Kan-Mitchell, J., B. Bisikirska, F. Wong-Staal, K. L. Schaubert, M. Bajcz, and M. Bereta. 2004. The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope. J. Immunol. 172:5249-5261.
37. Kohn, D. B. 2007. Lentiviral vectors ready for prime-time. Nat. Biotechnol. 25:65-66.
38. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
39. Langlade-Demoyen, P., N. Ngo-Giang-Huong, F. Ferchal, and E. Oksenhendler. 1994. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J. Clin. Investig. 93:1293-1297.
40. Levine, B. L., L. M. Humeau, J. Boyer, R. R. MacGregor, T. Rebello, X. Lu, G. K. Binder, V. Slepushkin, F. Lemiale, J. R. Mascola, F. D. Bushman, B. Dropulic, and C. H. June. 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103:17372-17377.
41. Lewis, D. E., D. S. Tang, A. Adu-Oppong, W. Schober, and J. R. Rodgers. 1994. Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J. Immunol. 153:412-420.
42. Lieberman, J., N. Manjunath, and P. Shankar. 2002. Avoiding the kiss of death: how HIV and other chronic viruses survive. Curr. Opin. Immunol. 14:478-486.
43. Lieberman, J., P. R. Skolnik, G. R. Parkerson III, J. A. Fabry, B. Landry, J. Bethel, and J. Kagan. 1997. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 90:2196-2206.
44. McMichael, A. J., and S. L. Rowland-Jones. 2001. Cellular immune responses to HIV. Nature 410:980-987.
45. Miles, J. J., S. L. Silins, and S. R. Burrows. 2006. Engineered T cell receptors and their potential in molecular medicine. Curr. Med. Chem. 13:2725-2736.
46. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis, and S. A. Rosenberg. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129.
47. Musey, L., J. Hughes, T. Schacker, T. Shea, L. Corey, and M. J. McElrath. 1997. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1267-1274.
48. Nijhuis, E. W., E. van de Wiel-van Kemenade, C. G. Figdor, and R. A. van Lier. 1990. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. Cancer Immunol. Immunother. 32:245-250.
49. Offringa, R. 2006. Cancer immunotherapy is more than a numbers game. Science 314:68-69.
50. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
51. Pantaleo, G., J. F. Demarest, H. Soudeyns, C. Graziosi, F. Denis, J. W. Adelsberger, P. Borrow, M. S. Saag, G. M. Shaw, R. P. Sekaly, et al. 1994. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370:463-467.
52. Phillips, R. E., S. Rowland-Jones, D. F. Nixon, F. M. Gotch, J. P. Edwards, A. O. Ogunlesi, J. G. Elvin, J. A. Rothbard, C. R. Bangham, C. R. Rizza, et al. 1991. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459.
53. Rinaldo, C., X.-L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
54. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, T. Corrah, et al. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64.
55. Rowland-Jones, S. L., T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi, J. Bwayo, K. S. MacDonald, A. J. McMichael, and F. A. Plummer. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Investig. 102:1758-1765.
56. Scholten, K. B., M. W. Schreurs, J. J. Ruizendaal, E. W. Kueter, D. Kramer, S. Veenbergen, C. J. Meijer, and E. Hooijberg. 2005. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin. Immunol. 114:119-129.
57. Sewell, A. K., G. C. Harcourt, P. J. Goulder, D. A. Price, and R. E. Phillips. 1997. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur. J. Immunol. 27:2323-2329.
58. + T cells to gut-associated lymphoid tissue during chronic infection. J. Virol. 77:5621-5631.
59. + T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate. J. Virol. 80:1850-1862.
60. Tan, R., X. Xu, G. S. Ogg, P. Hansasuta, T. Dong, T. Rostron, G. Luzzi, C. P. Conlon, G. R. Screaton, A. J. McMichael, and S. Rowland-Jones. 1999. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 93:1506-1510.
61. Ueno, T., M. Fujiwara, H. Tomiyama, M. Onodera, and M. Takiguchi. 2004. Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes. Eur. J. Immunol. 34:3379-3388.
62. Wang, E. J., M. Pettoello-Mantovani, C. M. Anderson, K. Osiecki, D. Moskowitz, and H. Goldstein. 2002. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells. J. Infect. Dis. 186:1412-1421.
63. Wolinsky, S. M., B. T. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsell, M. R. Furtado, Y. Cao, D. D. Ho, and J. T. Safrit. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542.
64. Yam, P. Y., S. Li, J. Wu, J. Hu, J. A. Zaia, and J. K. Yee. 2002. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol. Ther. 5:479-484.
65. Yang, O. O., S. A. Kalams, M. Rosenzweig, A. Trocha, N. Jones, M. Koziel, B. D. Walker, and R. P. Johnson. 1996. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J. Virol. 70:5799-5806.
66. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71:3120-3128.
67. Yang, O. O., and B. D. Walker. 1997. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv. Immunol. 66:273-311.
68. Yao, S., and L. Chen. 2006. Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends Mol. Med.
69. Yewdell, J. W. 2006. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 25:533-543.
70. Yewdell, J. W., and M. Del Val. 2004. Immunodominance in TCD8+ responses to viruses: cell biology, cellular immunology, and mathematical models. Immunity 21:149-153.